GlassScriptPhysician profile
Samir M Mazharuddin
NPI 1922442995
$30,048.82
in general payments reported to CMS, 2019-2025
67 companies · $7,735 in 2025
The $7,735 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,133 · 2020: $35.01 · 2021: $642 · 2022: $4,919 · 2023: $3,291 · 2024: $12K · 2025: $7,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $8,185 · Education: $248 · Honoraria: $200 · Travel and Lodging: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,554.70 |
| Food and Beverage | $8,184.68 |
| Education | $247.82 |
| Honoraria | $200.00 |
| Travel and Lodging | $132.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,996.05 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| Karyopharm Therapeutics INC. | $4,445.70 | 2024-2025 | Xpovio |
| Janssen Biotech, INC. | $4,198.47 | 2019-2025 | Darzalex, Erleada, Rybrevant |
| Morphosys, US INC. | $2,168.24 | 2022-2023 | Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $1,300.97 | 2021-2025 | Opdivo, Opdualag |
| Beigene USA, INC. | $932.18 | 2021-2024 | Brukinsa |
| Abbvie INC. | $772.12 | 2021-2025 | |
| Astellas Pharma US INC | $619.34 | 2019-2025 | Xtandi, Padcev, Xospata |
| Tempus Ai, INC | $596.44 | 2024-2025 | Xt Cdx |
| Celgene Corporation | $550.67 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $438.93 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Cardinal Health 110 LLC | $400.00 | 2025 | |
| Amgen INC. | $381.61 | 2019-2024 | Lumakras, Nplate, Xgeva |
| Pfizer INC. | $367.96 | 2023-2025 | |
| Daiichi Sankyo INC. | $322.92 | 2023-2025 | Enhertu, Datroway, Vanflyta |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $309.48 | 2019-2023 | Adcetris |
| Glaxosmithkline, LLC. | $295.20 | 2021-2025 | Ojjaara, Blenrep |
| Sobi, INC | $264.61 | 2024 | |
| Novartis Pharmaceuticals Corporation | $241.57 | 2021-2025 | |
| Eisai INC. | $239.39 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $199.43 | 2020-2025 | Darzalex, Tecvayli, Talvey |
| Genmab U.S., INC. | $169.05 | 2022-2025 | Tivdak, Epkinly |
| Aveo Pharmaceuticals, INC. | $164.34 | 2021-2025 | |
| Taiho Oncology, INC. | $163.42 | 2023-2025 | |
| Puma Biotechnology, INC. | $154.58 | 2023-2025 | |
| Genzyme Corporation | $151.95 | 2019-2024 | |
| Rigel Pharmaceuticals, INC. | $139.59 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Jazz Pharmaceuticals INC. | $136.16 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.59 | 2023-2025 | Alunbrig, Iclusig, Ninlaro |
| Astrazeneca Uk Limited | $121.99 | 2025 | Calquence |
| Cti Biopharma Corp. | $116.37 | 2022-2023 | Vonjo |
| Pharmacyclics LLC, An Abbvie Company | $110.74 | 2021-2023 | Imbruvica |
| Ipsen Biopharmaceuticals, INC | $104.33 | 2024-2025 | Onivyde, Tazverik |
| Gilead Sciences, INC. | $101.97 | 2023-2025 | Trodelvy |
| Stemline Therapeutics INC. | $89.92 | 2024-2025 | Orserdu |
| Lilly USA, LLC | $86.33 | 2024-2025 | Jaypirca, Verzenio |
| Tersera Therapeutics LLC | $75.09 | 2025 | Zoladex, Xermelo |
| Incyte Corporation | $69.50 | 2025 | Jakafi, Monjuvi, Niktimvo |
| Genentech USA, INC. | $69.14 | 2025 | Itovebi, Alecensa |
| Bayer Healthcare Pharmaceuticals INC. | $64.78 | 2025 | |
| Kite Pharma, INC. | $62.70 | 2025 | Yescarta |
| Pharmaessentia USA Corporation | $62.22 | 2024-2025 | Besremi |
| Array Biopharma INC | $57.87 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Deciphera Pharmaceuticals INC. | $50.90 | 2024-2025 | Qinlock, Tgct, Romvimza |
| Kyowa Kirin, INC. | $44.16 | 2023-2024 | Poteligeo |
| Mirati Therapeutics, INC. | $42.57 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $36.81 | 2025 | Libtayo, Lynozyfic |
| Springworks Therapeutics, INC. | $34.46 | 2024-2025 | Ogsiveo |
| Geron Corporation | $30.14 | 2024 | Rytelo |
| Boston Scientific Corporation | $29.06 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Acrotech Biopharma INC. | $27.91 | 2023 | Beleodaq |
| Emd Serono, INC. | $26.93 | 2025 | |
| Alnylam Pharmaceuticals INC. | $26.34 | 2025 | Givlaari |
| Fennec Pharmaceuticals, INC. | $24.35 | 2024 | Pedmark |
| Iovance Biotherapeutics, INC. | $23.78 | 2025 | Amtagvi |
| Janssen Pharmaceuticals, INC | $22.80 | 2023 | Xarelto |
| Pharming Healthcare, INC. | $21.99 | 2024 | Ruconest |
| Sumitomo Pharma America, INC. | $19.93 | 2023 | Orgovyx |
| Azurity Pharmaceuticals, INC. | $19.86 | 2025 | Danziten |
| Recordati_rare_diseases_inc. | $19.32 | 2025 | Enjaymo |
| Caris Mpi, INC. | $17.89 | 2025 | Mi Cancer Seek |
| Pharmaand Gmbh | $17.25 | 2025 | Rubraca |
| Tolmar, INC. | $17.25 | 2025 | Rubraca, Eligard |
| Sirtex Medical INC | $16.89 | 2022 | |
| Pharmacosmos Therapeutics INC. | $14.15 | 2024 | Monoferric |
| Adaptive Biotechnologies Corporation | $13.46 | 2025 | Clonoseq |
| Helsinn Therapeutics (U.S.), INC. | $12.71 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Mazharuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.